获得性免疫缺陷综合征相关淋巴瘤诊疗的研究进展

doi:10.3969/j.issn.1673-8640.2020.02.018

摘要/Abstract

摘要：

非霍奇金淋巴瘤（NHL）是一种常见的恶性肿瘤,约占淋巴瘤的90%。当人类免疫缺陷病毒（HIV）感染时会增加NHL的发生率,因此该类疾病被称为获得性免疫缺陷综合征相关淋巴瘤（ARL）。目前,ARL的发生、发展尚未形成定论,多数学者认为患者由于HIV感染,致使CD4⁺T细胞减少,免疫功能下降,进而导致ARL发生。因此,最新的治疗方法一般从源头上进行抗逆转录病毒治疗（ART）及免疫功能重建,同时采取针对淋巴瘤的R-CHOP方案。ARL患者需要选择合适的个体化治疗方案,且其预后转归往往大相径庭。文章拟对近年来ARL发病机制、治疗及预后的研究进展进行综述,为临床诊疗提供新思路。

Abstract:

Non-Hodgkin's lymphoma（NHL）,which accounts for 90% of lymphoma,is a common malignant tumor. When the body is infected with human immunodeficiency virus（HIV）,the incidence rate of NHL will increase. This type of disease is called acquired immune deficiency syndrome-related lymphoma（ARL）. At present,the occurrence and development of ARL has not been determined yet. Due to HIV infection,CD4⁺ T cells is reduced in patients with ARL,the immune status of patients is also disordered,and ARL occurs. Therefore,the new strategy of therapy focuses on antiviral therapy（ART） and the reconstruction of immune function with applying chemotherapy targeting to lymphoma by R-CHOP. Patients with ARL need to choose appropriate individualized tools,but the prognosis is often different. This review intends to summarize the studies on ARL,including mechanism,treatment and prognosis in recent years and provide new insights for clinical application.

Key words: Acquired immune deficiency syndrome-related lymphoma, Human immunodeficiency virus, Non-Hodgkin's lymphoma, Immunotherapy

中图分类号:

R446.1

刘懿萱, 郭林, 卢仁泉. 获得性免疫缺陷综合征相关淋巴瘤诊疗的研究进展[J]. 检验医学, 2020, 35(2): 173-177.

LIU Yixuan, GUO Lin, LU Renquan. Research progress of AIDS related lymphoma diagnosis and treatment[J]. Laboratory Medicine, 2020, 35(2): 173-177.

参考文献 37

[1]	GOEDERT J J.The epidemiology of acquired immunodeficiency syndrome malignancies[J]. Semin Oncol,2000,27(4):390-401.
[2]	BERAL V,PETERMAN T,BERKELMAN R,et al.AIDS-associated non-Hodgkin lymphoma[J]. Lancet,1991,337(8745):805-809.
[3]	MEISTER A,HENTRICH M,WYEN C,et al.Malignant lymphoma in the HIV-positive patient[J]. Eur J Haematol,2018,101(1):119-126.
[4]	ROBBINS H A,PFEIFFER R M,SHIELS M S,et al. Excess cancers among HIV-infected people in the United States[J]. J Natl Cancer Inst,2015,107(4):dju503.
[5]	YANIK E L,TAMBURRO K,ERON J J,et al.Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US,2000 to 2011[J]. Infect Agent Cancer,2013,8(1):18.
[6]	ARZOO K K,BU X,ESPINA B M,et al.T-cell lymphoma in HIV-infected patients[J]. J Acquir Immune Defic Syndr,2004,36(5):1020-1027.
[7]	VOGT S,PATEL M,OMAR T,et al.Molecular diagnostics for AIDS lymphoma diagnosis in south Africa and the potential for other low- and middle-income countries[J]. J Glob Oncol,2018,4:1-6.
[8]	MARKS M A,RABKIN C S,ENGELS E A,et al.Markers of microbial translocation and risk of AIDS-related lymphoma[J]. AIDS,2013,27(3):469-474.
[9]	EPELDEGUI M,VENDRAME E,MARTÍNEZ-MAZA O. HIV-associated immune dysfunction and viral infection:role in the pathogenesis of AIDS-related lymphoma[J]. Immunol Res,2010,48(1-3):72-83.
[10]	IMBEAULT M,OUELLET M,GIGUÈRE K,et al. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment[J]. J Virol,2011,85(5):2189-2200.
[11]	SHANNON-LOWE C,RICKINSON A B,BELL A I.Epstein-Barr virus-associated lymphomas[J]. Philos Trans R Soc B Biol Sci,2017,372(1732):20160271.
[12]	王迪,冯艳玲. HIV/AIDS 相关淋巴瘤研究进展[J]. 国际肿瘤学杂志,2015,42(6):475-477.
[13]	TANAKA P Y,OHSHIMA K,MATSUOKA M,et al.Epstein-barr viral load is associated to response in AIDS-related lymphomas[J]. Indian J Hematol Blood Transfus,2014,30(3):191-194.
[14]	OHMOTO A,MAESHIMA A M,TANIGUCHI H,et al.Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry[J]. Leuk Lymphoma,2015,56(12):3301-3305.
[15]	CHATTERJEE T,SOMASUNDARAM V.Flow cytometric detection of minimal residual disease in B-lineage acute lymphoblastic leukemia by using "MRD lite" panel[J]. Med J Armed Forces India,2017,73(1):54-57.
[16]	YOSHIDA N,ODA M,KURODA Y,et al.Clinical significance of sIL-2R levels in B-cell lymphomas[J]. PLoS One,2013,8(11):e78730.
[17]	WANG L,LIAO D Z,ZHANG J,et al.Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL):a predictive biomarker for treatment efficacy and valuable prognostic factor[J]. Med Oncol,2013,30(4):723.
[18]	ARMITAGE J O.Staging non-Hodgkin lymphoma[J]. CA Cancer J Clin,2005,55(6):368-376.
[19]	郑铁生,鄢盛恺. 临床生物化学检验[M]. 北京:中国医药科技出版社,2015.
[20]	MONTALBÁN C,ABRAIRA V,ARCAINI L,et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration,platelet count,high lactate dehydrogenase level and extrahilar lymphadenopathy:development and validation on 593 cases[J]. Br J Haematol,2012,159(2):164-171.
[21]	马肖容,徐燕,王瑾,等. 254例非霍奇金淋巴瘤的临床疗效与预后分析[J]. 中国实验血液学杂志,2016,24(4):1044-1050.
[22]	GASTAUD L,ROSSIGNOL B,PEYRADE F,et al.Role of radiotherapy in the management of non-Hodgkin lymphomas[J]. Cancer Radiother,2016,20(3):236-247.
[23]	杨小芸,沈丽达,龙庭凤,等. 1 326例非霍奇金淋巴瘤临床病理特点分析[J]. 中华肿瘤防治杂志,2016,23(9):605-609.
[24]	BARTA S K,SAMUEL M S,XUE X,et al.Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma[J]. Ann Oncol,2015,26(5):958-966.
[25]	HOFFMANN C J,GALLANT J E.Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels[J]. Infect Dis Clin North Am,2014,28(4):549-561.
[26]	CRUCIANI M,GATTI G,VACCHER E,et al.Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients[J]. J Antimicrob Chemother,2005,55(4):546-549.
[27]	SOMBOGAARD F,FRANSSEN E J F,TERPSTRA WE,et al. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma:a retrospective analysis[J]. Int J Clin Pharm,2018,40(5):1402-1408.
[28]	FOCÀ E,CAVAGLIÀ G,RUSCONI S,et al.Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment:an observational multicentre study[J]. HIV Med,2018,10:1111.
[29]	RIBERA J M,ORIOL A,MORGADES M,et al.Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma:results of a phase Ⅱ trial[J]. Br J Haematol,2008,140(4):411-419.
[30]	GOODMAN A,PATEL S P,KURZROCK R.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas[J]. Nat Rev Clin Oncol,2017,14(4):203-220.
[31]	CHANG E,RIVERO G,PATEL N R,et al.HIV-related refractory Hodgkin lymphoma:a case report of complete response to nivolumab[J]. Clin Lymphoma Myeloma Leuk,2018,18(2):e143-e146.
[32]	PHILIP T,GUGLIELMI C,HAGENBEEK A, et al.Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma[J]. N Eng J Med,1995,333(23):1540-1545.
[33]	RE A,CATTANEO C,ROSSI G.HIV and lymphoma:from epidemiology to clinical management[J]. Mediterr J Hematol Infect Dis,2019,11(1):e2019004.
[34]	刘保池,蔡瑞,朱同玉. 特殊感染外科新理念与新技术[M]. 上海:上海科技教育出版社,2017.
[35]	THOMPSON L D,FISHER M S I,CHU W S,et al. HIV-associated Hodgkin lymphoma:a clinicopathologic and immunophenotypic study of 45 cases[J]. Am J Clin Pathol,2004,121(5):727-738.
[36]	CARBONE A,GLOGHINI A,CARUSO A,et al.The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis[J]. Int J Cancer,2017,140(6):1233-1245.
[37]	AYALA E,CHAVEZ J C,GOMEZ A,et al.Feasibility and efficacy of high-dose chemotherapy and autologous hematopoietic cell transplantation for HIV-associated lymphoma:a single-institution experience[J]. Clin Lymphoma Myeloma Leuk,2018,18(8):548-551.